Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -0.5% (net) in the quarter compared to -7.7% return for iShares Russell 2000 Value Index and -9.5% return for the iShares Russell 2000 Index. In the quarter, Donald Trump’s aggressive tariff plans increased economic uncertainty. Although tariffs directly impact less than 5% of the portfolio, the firm was prepared for this situation. However, the widespread selling of stocks affected it significantly. The firm focuses on the fundamentally strong companies regardless of the economic environment. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Buckley Capital Advisors highlighted stocks such as Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company that engages in the development and commercialization of various products for unmet patient needs. The one-month return of Liquidia Corporation (NASDAQ:LQDA) was 25.46%, and its shares gained 24.56% of their value over the last 52 weeks. On May 7, 2025, Liquidia Corporation (NASDAQ:LQDA) stock closed at $15.53 per share with a market capitalization of $1.326 billion. Buckley Capital Advisors stated the following regarding Liquidia Corporation (NASDAQ:LQDA) in its Q1 2025 investor letter: "Liquidia Corporation (NASDAQ:LQDA): Pulmonary arterial hypertension (PAH) is a serious and potentially life-threatening lung disease whose root causes span a wide range, from hereditary factors to underlying cardiovascular health conditions to systemic diseases like HIV and connective tissue disorders. PAH impacts an estimated half a million individuals around the globe, with around 50,000 American patients currently under treatment. An aerial view of a biopharmaceutical manufacturing plant, signifying the company's expansive operations. Story Continues Liquidia Corporation (NASDAQ:LQDA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held Liquidia Corporation (NASDAQ:LQDA) at the end of the fourth quarter, compared to 28 in the third quarter. While we acknowledge the potential of Liquidia Corporation (NASDAQ:LQDA) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Liquidia Corporation (NASDAQ:LQDA) and shared Jim Cramer’s hidden gems and undervalued stocks you need to know. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Buckley Capital’s Views on Liquidia Corp. (LQDA)
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...